Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
5.96
-0.34 (-5.40%)
At close: May 15, 2026, 4:00 PM EDT
6.08
+0.12 (2.01%)
After-hours: May 15, 2026, 7:58 PM EDT

Taysha Gene Therapies Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
May '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
1,7131,568355331141448
Market Cap Growth
226.25%342.19%7.14%134.50%-68.52%-55.28%
Enterprise Value
1,6021,316276.37245.99111.65362.21
Last Close Price
5.965.501.731.772.2611.65
PE Ratio
--16.18-4.81-1.84-0.60-2.51
PS Ratio
242.32160.4242.5521.4256.40-
PB Ratio
8.546.354.964.42148.704.70
P/TBV Ratio
9.677.126.052.74104.674.60
P/FCF Ratio
--16.71-4.35-4.30-1.29-3.39
P/OCF Ratio
--16.84-4.37-4.53-1.60-3.83
EV/Sales Ratio
214.48134.6433.1715.9244.62-
EV/EBITDA Ratio
--12.03-3.06-3.46-0.69-2.10
EV/EBIT Ratio
--11.91-3.02-3.40-0.69-2.09
EV/FCF Ratio
--14.02-3.39-3.20-1.02-2.74
Debt / Equity Ratio
0.310.280.860.7961.550.66
Debt / EBITDA Ratio
-0.51-0.62-0.68-0.84-0.36-0.36
Debt / FCF Ratio
-0.59-0.73-0.75-0.77-0.54-0.48
Net Debt / Equity Ratio
-0.99-1.02-1.09-1.13-31.06-0.90
Net Debt / EBITDA Ratio
1.602.300.871.200.180.50
Net Debt / FCF Ratio
1.872.690.961.110.270.65
Asset Turnover
0.020.040.050.100.010
Quick Ratio
13.7812.065.323.931.402.88
Current Ratio
14.0412.235.424.081.543.08
Return on Equity (ROE)
-56.61%-68.45%-121.94%-294.04%-344.67%-100.68%
Return on Assets (ROA)
-41.19%-43.88%-54.91%-48.45%-95.49%-73.29%
Return on Invested Capital (ROIC)
120512.00%-22619.90%-1295.73%-768.38%-1458.89%-2546.92%
Return on Capital Employed (ROCE)
-44.41%-49.01%-67.72%-72.63%-143.95%-83.71%
Earnings Yield
-7.17%-6.18%-20.81%-54.24%-167.26%-39.83%
FCF Yield
-6.20%-5.98%-23.01%-23.23%-77.25%-29.53%
Buyback Yield / Dilution
-32.50%-27.82%-115.41%-164.20%-16.74%-113.13%
Total Shareholder Return
-32.50%-27.82%-115.41%-164.20%-16.74%-113.13%
Updated May 6, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q